Doximity Crashes 21% to Multi-Year Lows: AI Cost Inflation Breaks the SaaS Margin Story

Event Summary

According to Business Wire and Doximity's official investor relations, the company released Q4 FY2026 results on May 13, 2026, revealing a critical divergence: revenue of $145.4M beat consensus by $1.3M (+5% YoY), but adjusted EPS of $0.26 missed the $0.28 consensus by 7.1%. More damaging was the forward guidance — FY2027 revenue of $664–676M implies only ~4% growth versus FY2026's 13%, while adjusted EBITDA margin is guided to compress 600 basis points (55% → 49%). As reported by Benzinga, KeyBanc downgraded DOCS and multiple analysts slashed price targets on May 14. The stock fell 21.3% to $23, reaching multi-year lows.

The culprit is AI compute costs. As nearly 400,000 of Doximity's 800,000+ active prescribers now use clinical AI tools — with AI prompts per user nearly doubling from January to April 2026 — inference and infrastructure expenses are compressing margins faster than revenue can offset. This is a textbook earnings miss revenue shock pattern: headline beat masking structural margin deterioration.

Leverage Impact Analysis

For traders using CoinUnited.io's stock CFDs, DOCS's 21.3% single-session drop creates extreme leverage risk in both directions. Consider a trader who opened a 50x long DOCS CFD at $29 (pre-earnings): the 21.3% decline to $23 represents a ~73% move against a 2% margin buffer, resulting in full liquidation well before the close. Even a 10x long from $29 would face a margin call with the stock down over 20%.

Short-side traders with 20x short DOCS CFDs opened near $28 would have seen approximately 400% return on margin from the move to $23 — but only if stops were managed above the pre-earnings price. The earnings miss trading guide framework applies here: post-earnings gap-down stocks often see continuation selling as analyst downgrades layer in, but violent short-covering bounces are common within 48–72 hours at multi-year lows. Position sizing should reflect this binary risk. Monitor open interest for confirmation signals on CoinUnited.io.

Cross-Market Impact

The DOCS selloff carries sector-wide implications beyond a single stock. Healthcare IT and digital health ETFs — including ARKK (which holds Doximity), XBI, and IBB — face contagion pressure as AI monetization ROI concerns spread. The broader narrative that AI infrastructure capital reallocation drives margin compression — not just expansion — is now embedded in SaaS valuations.

For the NASDAQ 100 and S&P 500, the signal is nuanced: DOCS is a small-cap name, so direct index drag is limited. However, its AI cost narrative pressures the broader SaaS multiple, particularly names with heavy clinical or enterprise AI deployment. NVIDIA and cloud providers (MSFT Azure, AWS) receive a demand-confirmation signal from Doximity's GPU usage surge — but margin compression at the application layer caps enthusiasm. Teladoc Health (TDOC) and similar digital health platforms are the clearest sector contagion targets. Policy uncertainty cited in Doximity's guidance also weighs on pharma advertising-dependent healthcare platforms.

Trading Considerations

DOCS is now trading at $23 with no established technical support at current levels given the multi-year low print. The TIKR model price target of $35 implies 52% upside, but forward guidance deceleration (13% → 4% growth) and 600 bps EBITDA margin compression must be re-rated first. Key upside triggers: Q1 FY2027 results (expected late August 2026) showing AI cost stabilization, or evidence that the 109% net revenue retention and $493M remaining buyback authorization provide a price floor.

Downside risks remain elevated: soft HCP digital pharma ad demand and policy uncertainty show no near-term resolution. Traders should watch whether the $23 level holds on volume or if sector ETF (XBI, ARKK) selling accelerates. For earnings miss recovery plays, see the dedicated trader framework.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.